All In Biotech

Drug Trial Radar · NCT05682170

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor ZN-c3 in Subjects With Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

40

Actual

Start

Dec 1, 2022

Primary completion

Jul 2, 2024

Study completion Jul 26, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia (AML).

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • ZN-d5 ZN-c3Drug

    Oral agent

  • ZN-c3Drug

    Oral agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Observed dose limiting toxicitiesTime frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Incidence, severity, and relatedness of adverse events( AEs)Time frame: Through study completion, typically < 12 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California San Francisco

    San Francisco, California

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • NYU Langone Health

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Albert Einstein College of Medicine - Montefiore Medical Center

    The Bronx, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • James Cancer Hospital and Solove Research Institute

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Tristar Bone Marrow Transplant

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • The Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.